<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We quantitatively investigated the clinical severity and progression of diseases with <z:hpo ids='HP_0001251'>ataxia</z:hpo>, as measured with the Scale for the Assessment and Rating of <z:hpo ids='HP_0001251'>Ataxia</z:hpo>, and examined the potential application of the Scale for the Assessment and Rating of <z:hpo ids='HP_0001251'>Ataxia</z:hpo> for future therapeutic trials </plain></SENT>
<SENT sid="1" pm="."><plain>Severity of <z:hpo ids='HP_0001251'>ataxia</z:hpo> was assessed in 238 patients with spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 2, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 6, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 17, multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant, or Gerstman-Sträussler-Scheinker disease </plain></SENT>
<SENT sid="2" pm="."><plain>Among them, 119 (50%) were longitudinally examined three to seven times, in a period of 8 to 38 months, resulting in a total set of 535 assessments </plain></SENT>
<SENT sid="3" pm="."><plain>The differences between spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> and multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant were ascertained cross-sectionally and longitudinally </plain></SENT>
<SENT sid="4" pm="."><plain>Gerstman-Sträussler-Scheinker disease had the fastest progression, followed by multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 17, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3, spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 2, and spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 6 </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant had a faster progression in gait, sitting, speech, and total score than patients with spinocerebellar <z:hpo ids='HP_0001251'>ataxias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>For a randomized, case-control trial, a sample size of 47 for spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> and 85 for multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant in the treatment or placebo arms would have a sufficient statistical power to demonstrate the efficacy of a new therapy that would retard <z:hpo ids='HP_0001251'>ataxia</z:hpo> progression by 1 point per year as measured by the Scale for the Assessment and Rating of <z:hpo ids='HP_0001251'>Ataxia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The results will have a significant impact on the planning and implementation of future therapeutic trials of spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> and multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar variant </plain></SENT>
</text></document>